To counteract the effects of the highly expressed FGF2/FGFR1 pathway, research indicates that VEGF-B can act as a unique angiogenic factor; although it typically has limited angiogenic activity, it can inhibit tumor growth and angiogenesis under specific conditions by suppressing FGF2-induced Erk phosphorylation and thus reducing FGF2-driven angiogenesis (66, 67). The gene discussed is FGF2; the disease is neoplasm.